Schwartz L H, Koerner F C, Edgerton S M, Sawicka J M, Rio M C, Bellocq J P, Chambon P, Thor A D
Department of Radiation Therapy, Massachusetts General Hospital, Harvard Medical School, Boston 02114.
Cancer Res. 1991 Jan 15;51(2):624-8.
Seventy-two patients with advanced breast carcinoma (42% bone, 25% visceral, 5.5% soft tissue, and 27.5% multiple site metastases) were evaluated to determine the relationship between tumor expression of the estrogen-regulated protein pS2, estrogen receptor (ER) or progesterone receptor (PgR) content, and response to hormonal therapy. Twenty-nine % of tumors were pS2 positive, 64% were ER positive, and 29% were PgR positive. Of the ER-positive patients (n = 43), 15 (35%) had greater than 10% of the invasive carcinoma which immunostained for pS2 (these were considered pS2 positive). Only 3 of 24 ER-negative tumors were pS2 positive. A weak association between pS2 expression and ER content (P = 0.08) but not PgR content was observed. Of pS2-positive patients, 52% had a partial or complete response to hormonal therapy. In 24% of pS2-positive patients the disease stabilized with treatment. In contrast, 27% of pS2-negative patients had a partial or complete response. In 10% of these patients the disease stabilized. Similar associations between therapeutic response and ER or PgR were not observed. The odds of having a clinical response to hormonal therapy was greater for pS2-positive than for ER- or PgR-positive tumors. pS2 expression may define a subset of ER-positive tumors that are more likely to respond to hormonal treatment.
对72例晚期乳腺癌患者（42%有骨转移，25%有内脏转移，5.5%有软组织转移，27.5%有多处转移）进行评估，以确定雌激素调节蛋白pS2的肿瘤表达、雌激素受体（ER）或孕激素受体（PgR）含量与激素治疗反应之间的关系。29%的肿瘤pS2呈阳性，64%的ER呈阳性，29%的PgR呈阳性。在ER阳性患者（n = 43）中，15例（35%）的浸润性癌中有超过10%对pS2免疫染色呈阳性（这些被视为pS2阳性）。24例ER阴性肿瘤中只有3例pS2呈阳性。观察到pS2表达与ER含量之间存在弱关联（P = 0.08），但与PgR含量无关联。在pS2阳性患者中，52%对激素治疗有部分或完全反应。在24%的pS2阳性患者中，疾病经治疗后稳定。相比之下，27%的pS2阴性患者有部分或完全反应。在这些患者中，10%的疾病稳定。未观察到治疗反应与ER或PgR之间有类似关联。pS2阳性肿瘤对激素治疗产生临床反应的几率高于ER或PgR阳性肿瘤。pS2表达可能定义了一个更可能对激素治疗有反应的ER阳性肿瘤亚组。
